DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

Epizyme (NASDAQ: EPZM)

22.31 -0.02 (-0.09%)

Quote as of


company name or ticker

Recent Quotes

EPZM $22.31 -0.09%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.42
Previous Close $22.33
Daily Range $22.06 - $23.35
52-Week Range $15.51 - $40.98
Market Cap $919.3M
P/E Ratio -6.98
Dividend (Yield) $0.00 (0.0%)
Volume 189,037
Average Daily Volume 725,216
Current FY EPS -$3.58

Sector

Industry

Epizyme (EPZM) Description

Epizyme Inc is a clinical stage biopharmaceutical company that discovers develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. Website: http://www.epizyme.com/

News & Commentary Rss Feed

Why Epizyme Inc. Shares Are Soaring

Epizyme Inc. has reported intriguing early stage trial results in non-Hodgkin lymphoma.

H.C. Wainwright Destroys Epizyme Price Target, Sees 'No Material Value Drivers'

Analysts' Actions -- Amazon, Hertz and Kraft Heinz

Celgene: Is This Range Bound Stock Ready To Go Higher?

Epizyme Partnership With Celgene Makes It Worth A Look

Epizyme/Celgene Extend Research Deal for HMT Inhibitors - Analyst Blog

Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat

Epizyme Doses First Patient in Five-Arm Phase 2 Study for First-in-Class EZH2 Inhibitor Tazemetostat (EPZ-6438) in Relapsed or Refractory Non-Hodgkin Lymphoma

Celgene Rapid Growth Is Still Ahead For 2016 Through 2020

Strong On High Relative Volume: Epizyme (EPZM)

RBC Capital Initiates Epizyme With Outperform

Today's Perilous Reversal Stock: Epizyme (EPZM)

See More EPZM News...